Parkinson's Disease — Indication Intelligence | Humanexa Signals

ClinicalAugust 19, 2026

Phase 2 Study of SUL-238 in Early Untreated Parkinson's Disease Initiated by GEN İlaç

GEN İlaç ve Sağlık Ürünleri A.Ş. has initiated Phase 2 clinical trial to evaluate the efficacy and safety of SUL-238 in patients with early, untreated Parkinson's Disease, using ³¹P-MRS to assess mitochondrial function.

ClinicalAugust 13, 2026

University of Alabama at Birmingham Initiates Longitudinal Study on [18F]DPA-714 in Parkinson's Disease

[18F]DPA-714 PET imaging study initiated to assess binding in prodromal and early Parkinson's Disease over 24 months.

RegulatoryAugust 12, 2026

FDA accepts supplemental application for Carbidopa and Levodopa by Apotex

The FDA has accepted a supplemental application (ANDA077120) for Carbidopa and Levodopa submitted by Apotex Inc.

RegulatoryAugust 11, 2026

FDA approves supplemental application for CARBIDOPA and LEVODOPA by Rubicon Research

The FDA has approved the supplemental application ANDA217482 for CARBIDOPA and LEVODOPA submitted by Rubicon Research. This approval allows Rubicon to market its formulation in the Parkinson's Disease treatment space, where CARBIDOPA and LEVODOPA are already established therapies.

RegulatoryAugust 11, 2026

FDA grants supplemental approval for Impax Labs' Carbidopa and Levodopa

The FDA has granted supplemental approval for Impax Labs' ANDA076521 for Carbidopa and Levodopa.

RegulatoryAugust 9, 2026

FDA Accepts Supplement for Apomorphine Hydrochloride NDA214056

The FDA has accepted a supplemental application for Apomorphine Hydrochloride under NDA214056.

RegulatoryAugust 9, 2026

FDA Accepts Supplement for CREXONT (Carbidopa/Levodopa) by IMPAX

The FDA has accepted a supplemental application for CREXONT, a combination of carbidopa and levodopa, from IMPAX.

ClinicalAugust 9, 2026

Study on Long Term Effectiveness of LECIGON® in Advanced Parkinson's Disease

The study aims to evaluate the effectiveness of LECIGON® in reducing OFF time in patients with advanced Parkinson's Disease over 12 months.

RegulatoryAugust 6, 2026

Aurobindo Pharma's Carbidope and Levodopa Supplement Application Receives Standard Review Status

Aurobindo Pharma's supplemental application for Carbidope and Levodopa has been submitted and is under standard review.

RegulatoryAugust 6, 2026

FDA Submission for Carbidope and Levodopa by Biocon Pharma Limited

Biocon Pharma Limited has submitted an original application (ANDA220119) for Carbidope and Levodopa.

ClinicalAugust 3, 2026

Exploratory Study of UX-DA001 in Parkinson's Disease Shows Potential for Motor Function Improvement

The study aims to assess the safety, tolerability, and efficacy of UX-DA001 in improving motor function in Parkinson's disease patients.

RegulatoryJuly 31, 2026

FDA Grants Priority Review for NUPLAZID Supplement NDA210793

The FDA has granted priority review status for the supplemental NDA for NUPLAZID, an indication for pimavanserin tartrate.

RegulatoryJuly 31, 2026

FDA grants priority review for NUPLAZID supplemental application

The FDA has granted priority review status for the supplemental application of NUPLAZID (pimavanserin tartrate) submitted by ACADIA Pharmaceuticals.

ClinicalJuly 22, 2026

Study on rTMS and Olfactory Training for Parkinson's Disease Shows Promise

A clinical trial is evaluating the efficacy of rTMS combined with olfactory training in Parkinson's patients to restore chemosensory function.

RegulatoryJuly 21, 2026

FDA Grants AP Status for Carbidope and Levodopa Supplement by Rubicon Research

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for a supplement involving Carbidope and Levodopa by Rubicon Research.

RegulatoryJuly 21, 2026

Impax Labs Receives AP Status for Carbidope and Levodopa Supplement

Impax Labs has received an Abbreviated Approval (AP) for a supplement application of Carbidope and Levodopa.

RegulatoryJuly 21, 2026

Apotex submits supplemental ANDA for Carbidopa and Levodopa

Apotex Inc. has submitted a supplemental abbreviated new drug application (ANDA077120) for Carbidopa and Levodopa.

ClinicalJuly 21, 2026

Hoffmann-La Roche's Prasinezumab Trial Targets Early-Stage Parkinson's Disease

A clinical trial is underway to assess the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease patients.

ClinicalJuly 20, 2026

Aquatic HIIT Trial for Parkinson's Disease Shows Potential Benefits

A randomized trial is assessing the impact of an 8-week aquatic HIIT program on patients with Parkinson's disease.

ClinicalJuly 19, 2026

Study on Deep Brain Stimulation's Impact on Eye Function in Parkinson's Disease

The study investigates the effects of deep brain stimulation on vergence impairment and strabismus in Parkinson's patients.

RegulatoryJuly 19, 2026

FDA Accepts Supplement for Apomorphine Hydrochloride NDA214056

The FDA has accepted a supplemental application for Apomorphine Hydrochloride under NDA214056.

RegulatoryJuly 18, 2026

FDA Accepts Supplemental NDA for CREXONT by IMPAX

The FDA has accepted a supplemental NDA for CREXONT, a combination of carbidope and levodopa.

RegulatoryJuly 16, 2026

FDA Grants AP Status for Amantadine Hydrochloride ANDA210215

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Amantadine Hydrochloride submitted by POM Pharma.

ClinicalJuly 14, 2026

Phase III Trial of Lecigon® in Parkinson's Disease Targets Neuropsychiatric Symptoms

A Phase III trial is underway to evaluate the efficacy of Lecigon® in reducing hyperdopaminergic symptoms in Parkinson's patients.

RegulatoryJuly 14, 2026

Aurobindo Pharma's ANDA216537 for Carbidope and Levodopa Receives AP Status

Aurobindo Pharma's ANDA216537 for a supplemental application of Carbidope and Levodopa has received an Abbreviated Approval (AP) status from the FDA.

ClinicalJuly 13, 2026

Phase 2b Study of Pirepemat Shows Promise for Reducing Falls in Parkinson's Patients

A Phase 2b clinical trial is underway to evaluate the efficacy and safety of pirepemat in reducing falls in Parkinson's disease patients.

ClinicalJuly 13, 2026

NeuroDerm's ND0612 Study Evaluates Safety and Pharmacokinetics in Parkinson's Disease

A randomized, placebo-controlled study is underway to assess the safety and pharmacokinetics of ND0612 in Parkinson's disease patients.

RegulatoryJuly 12, 2026

FDA Accepts Supplement for INBRIJA (Levodopa) by Merz

The FDA has accepted a supplemental application for INBRIJA, an inhaled formulation of levodopa, submitted by Merz.

RegulatoryJuly 9, 2026

FDA Accepts Supplemental NDA for ONAPGO (Apomorphine Hydrochloride)

The FDA has accepted a supplemental NDA for ONAPGO, indicating progress in regulatory review.

RegulatoryJuly 8, 2026

FDA Submission Update for CARBIDOPA; LEVODOPA by Zydus Pharms

Zydus Pharms USA Inc. has submitted an original application for CARBIDOPA; LEVODOPA under ANDA210911.

ClinicalJuly 8, 2026

Novel Remote Rehab Technique for Parkinson's Disease in Veterans

A new remote dynamic cycling rehabilitation technique is being tested for its efficacy in Parkinson's disease patients.

RegulatoryJuly 7, 2026

FDA Accepts Supplemental NDA for NUPLAZID by ACADIA PHARMS

The FDA has accepted a supplemental NDA for NUPLAZID (pimavanserin tartrate) from ACADIA Pharmaceuticals.

ClinicalJuly 7, 2026

Study on SuPerSense Proprioceptive Rehabilitation in Parkinson's Disease

A randomized controlled trial is evaluating the feasibility and efficacy of the SuPerSense device for proprioceptive rehabilitation in Parkinson's disease.

ClinicalJuly 3, 2026

Study on Bottle PEP Device Effects in Parkinson's Disease Patients

A clinical trial is investigating the impact of a low-cost bottle-PEP device on expiratory muscle strength and balance in Parkinson's disease patients.

ClinicalJuly 3, 2026

Study on Automated Parameter Optimization for Adaptive DBS in Parkinson's Disease

A new clinical trial aims to optimize adaptive deep brain stimulation (aDBS) parameters for Parkinson's disease patients using an automated, data-driven approach.

RegulatoryJuly 1, 2026

FDA Grants AP Status for Carbidope and Levodopa Supplement by Rubicon Research

The FDA has granted an Abbreviated New Drug Application (ANDA) AP status for a supplement of Carbidope and Levodopa submitted by Rubicon Research.

ClinicalJune 30, 2026

Study on Vagus Nerve Stimulation in Parkinson's Disease Underway

A clinical trial is investigating the effects of transcutaneous vagus nerve stimulation on gut-brain communication in Parkinson's disease patients.

ClinicalJune 23, 2026

Trial Compares VR and Dual-Task Training for Balance in Parkinson's Disease

A clinical trial is evaluating the efficacy of cognitive-based balance rehabilitation using Virtual Reality versus traditional Dual-Task Training in Parkinson's Disease patients.

ClinicalJune 23, 2026

Clinical Trial Evaluates Adaptive DBS for Parkinson's Disease Management

A clinical trial is underway to assess the efficacy and safety of an adaptive deep brain stimulation system for Parkinson's disease.

Relevant assets

Relevant companies

Recent signals(39)

Phase 2 Study of SUL-238 in Early Untreated Parkinson's Disease Initiated by GEN İlaç

University of Alabama at Birmingham Initiates Longitudinal Study on [18F]DPA-714 in Parkinson's Disease

FDA accepts supplemental application for Carbidopa and Levodopa by Apotex

FDA approves supplemental application for CARBIDOPA and LEVODOPA by Rubicon Research

FDA grants supplemental approval for Impax Labs' Carbidopa and Levodopa

FDA Accepts Supplement for Apomorphine Hydrochloride NDA214056

FDA Accepts Supplement for CREXONT (Carbidopa/Levodopa) by IMPAX

Study on Long Term Effectiveness of LECIGON® in Advanced Parkinson's Disease

Aurobindo Pharma's Carbidope and Levodopa Supplement Application Receives Standard Review Status

FDA Submission for Carbidope and Levodopa by Biocon Pharma Limited

Exploratory Study of UX-DA001 in Parkinson's Disease Shows Potential for Motor Function Improvement

FDA Grants Priority Review for NUPLAZID Supplement NDA210793

FDA grants priority review for NUPLAZID supplemental application

Study on rTMS and Olfactory Training for Parkinson's Disease Shows Promise

FDA Grants AP Status for Carbidope and Levodopa Supplement by Rubicon Research

Impax Labs Receives AP Status for Carbidope and Levodopa Supplement

Apotex submits supplemental ANDA for Carbidopa and Levodopa

Hoffmann-La Roche's Prasinezumab Trial Targets Early-Stage Parkinson's Disease

Aquatic HIIT Trial for Parkinson's Disease Shows Potential Benefits

Study on Deep Brain Stimulation's Impact on Eye Function in Parkinson's Disease

FDA Accepts Supplement for Apomorphine Hydrochloride NDA214056

FDA Accepts Supplemental NDA for CREXONT by IMPAX

FDA Grants AP Status for Amantadine Hydrochloride ANDA210215

Phase III Trial of Lecigon® in Parkinson's Disease Targets Neuropsychiatric Symptoms

Aurobindo Pharma's ANDA216537 for Carbidope and Levodopa Receives AP Status

Phase 2b Study of Pirepemat Shows Promise for Reducing Falls in Parkinson's Patients

NeuroDerm's ND0612 Study Evaluates Safety and Pharmacokinetics in Parkinson's Disease

FDA Accepts Supplement for INBRIJA (Levodopa) by Merz

FDA Accepts Supplemental NDA for ONAPGO (Apomorphine Hydrochloride)

FDA Submission Update for CARBIDOPA; LEVODOPA by Zydus Pharms

Novel Remote Rehab Technique for Parkinson's Disease in Veterans

FDA Accepts Supplemental NDA for NUPLAZID by ACADIA PHARMS

Study on SuPerSense Proprioceptive Rehabilitation in Parkinson's Disease

Study on Bottle PEP Device Effects in Parkinson's Disease Patients

Study on Automated Parameter Optimization for Adaptive DBS in Parkinson's Disease

FDA Grants AP Status for Carbidope and Levodopa Supplement by Rubicon Research

Study on Vagus Nerve Stimulation in Parkinson's Disease Underway

Trial Compares VR and Dual-Task Training for Balance in Parkinson's Disease

Clinical Trial Evaluates Adaptive DBS for Parkinson's Disease Management

Upcoming catalysts

Therapeutic areas

Get signals before the market moves